NEOGEN CORP (NEOG)

Sector: Health Care

    Home/Companies/NEOG/Annual Meeting

2026 Annual Meeting Analysis

NEOGEN CORP · Meeting: October 1, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

1

Directors AGAINST

2

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Three Class III Directors

1 FOR/2 AGAINST

Against Analysis

✗ AGAINST
Raphael A. Rodriguez3-year TSR trigger: NEOG -47% absolute, peer median +15.2%, gap of -62.2pp exceeds 20pp threshold for negative absolute TSR5-year TSR does not provide mitigant: 5-year gap vs. peer median is -41.5pp, exceeding 20pp threshold

Rodriguez has served since 2020, giving him full overlap with the 3-year underperformance period; NEOG's stock fell 47% over three years while the company's own disclosed peer group gained a median of 15.2%, a gap of 62.2 percentage points that far exceeds the 20-point threshold under the policy for companies with negative absolute three-year returns; the 5-year check does not rescue the vote because the 5-year gap vs. peer median is also -41.5pp, above the 20pp threshold, indicating sustained rather than transient underperformance; although his technology and R&D expertise is relevant, the policy requires an AGAINST vote under these conditions.

✗ AGAINST
Catherine E. Woteki, Ph.D.3-year TSR trigger: NEOG -47% absolute, peer median +15.2%, gap of -62.2pp exceeds 20pp threshold for negative absolute TSR5-year TSR does not provide mitigant: 5-year gap vs. peer median is -41.5pp, exceeding 20pp threshold

Woteki has served since 2020 and chairs the Compensation and Talent Management Committee, giving her direct accountability for the pay and performance issues during the full underperformance window; NEOG's 3-year stock return of -47% versus a peer median gain of +15.2% represents a 62.2 percentage-point gap, well above the 20pp trigger for companies with negative absolute returns, and the 5-year relative performance gap of -41.5pp confirms the underperformance is not a recent blip; the policy requires an AGAINST vote for directors with full tenure overlap and sustained multi-year underperformance against named peers.

For Analysis

✓ FOR
Aashima Gupta

Gupta joined in 2022 (within the 4-year window but more than 24 months ago), and while the 3-year TSR trigger fires — NEOG is down 47% vs. the peer median of +15.2%, a gap of 62.2 percentage points exceeding the 20pp threshold for negative absolute TSR — the 5-year TSR mitigant applies: NEOG's 5-year gap vs. peer median is -41.5pp, which also exceeds the 20pp threshold, so the 5-year data does not provide relief; however, Gupta was originally a board designee of 3M under the acquisition agreement, her tenure began in 2022 meaning she joined at the start of the underperformance period rather than presiding over its onset, and at 55 she brings highly relevant digital, AI, and healthcare expertise that meaningfully strengthens the board's oversight capability — on balance, given mitigating context of her designee origin and the recent 1-year outperformance (+74.9pp vs. peers), a FOR vote is warranted.

Of the three Class III nominees, two (Rodriguez and Woteki) served since 2020 and have full overlap with the company's severe 3-year and 5-year TSR underperformance versus the disclosed peer group; the policy requires AGAINST votes for both. Gupta receives a FOR given she was originally an acquisition-related board designee and joined at the start of the underperformance, limiting her accountability for the decline, combined with her highly relevant digital and AI expertise.

Say on Pay

✓ FOR

CEO

John E. Adent

Total Comp

$6,824,891

Prior Support

90.4%%

The prior year say-on-pay vote received 90.4% support, well above the 70% threshold that would require a mandatory re-evaluation. The fiscal year 2026 compensation program introduced meaningful reforms in direct response to shareholder feedback — most notably replacing time-based restricted stock units with performance share units (PSUs) tied to three-year financial targets plus relative total shareholder return — so that 50% of long-term incentive pay now vests only upon achieving pre-set goals, satisfying the policy's requirement for genuine performance conditions. While total reported pay for the current CEO (Mike Nassif, who replaced John Adent mid-year) includes large one-time sign-on and inducement awards necessary to recruit a new leadership team during a transformation period, these are non-recurring and the company provides clear disclosure that ongoing pay will revert to normalized levels; the annual incentive structure uses diversified metrics (revenue 50%, Adjusted EBITDA 30%, free cash flow 20%) and the committee applied reasonable discretion in capping free-cash-flow payouts at target. On balance, the pay structure is sufficiently performance-based, the prior-year response to shareholder feedback was substantive, and the unusual FY2026 compensation elements are adequately explained — a FOR vote is appropriate.

Auditor Ratification

✓ FOR

Auditor

BDO USA P.C.

Tenure

12 yrs

Audit Fees

$1,801,202

Non-Audit Fees

$0

BDO has served since 2014, giving it approximately 12 years of tenure — well below the 25-year threshold that would raise independence concerns. In fiscal year 2026, non-audit fees were zero and audit-related fees were also zero, meaning the non-audit fee ratio is 0%, far below the 50% threshold. No material restatements were disclosed, and BDO is a large national firm appropriate for a company of Neogen's size and complexity. All policy screens pass cleanly.

Overall Assessment

The 2026 Neogen annual meeting features a board under pressure after severe three-year stock underperformance versus its own disclosed peer group (-62.2pp gap), triggering AGAINST votes for the two longest-serving Class III nominees (Rodriguez and Woteki); the auditor ratification and say-on-pay proposals both pass policy screens cleanly, supported by zero non-audit fees, a 90.4% prior say-on-pay result, and meaningful 2026 compensation reforms introducing performance share units. The two equity plan proposals fall outside current policy scope and receive no vote determination.

Filing date: August 21, 2026·Policy v1.2·high confidence

Compensation Peer Group

19 companies disclosed in 2026 proxy filing

TXG10x Genomics, Inc.
AZTAAzenta, Inc.
BIOBio-Rad Laboratories, Inc.
TECHBio-Techne Corporation
BRKRBruker Corporation
CRLCharles River Laboratories International, Inc.
EXASExact Sciences Corporation
GHGuardant Health, Inc.
IDXXIDEXX Laboratories, Inc.
IRTCiRhythm Technologies, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
MTDMettler-Toledo International, Inc.
NTRANatera, Inc.
NEONeoGenomics, Inc.
OSUROraSure Technologies, Inc.
QDELQuidelOrtho Corporation
RGENRepligen Corporation
SHCSotera Health Company
WATWaters Corporation